FDA's New Drug-Review Rules Raise Concerns Over Transparency and Decision-Making

The recent changes to the drug-review process at the U. S. Food and Drug Administration (FDA) have sparked concerns about the potential for increased opacity and arbitrary decision-making. Bloomberg posted on X, highlighting the challenges that pharmaceutical companies and investors may face in modeling and planning due to these new rules source: https://www.binance.com/en/square/post/289811362009970?utm_source=BinanceNewsRSS